127-Patient Trial of Casdatifan Shows Durable Responses in Advanced Kidney Cancer

For health systems grappling with the rising burden of advanced kidney cancer, novel targeted therapies offer a chance to shift from trial-and-error treatment to precision medicine. Casdatifan’s signal of durable responses in a heavily pretreated population—if confirmed in later trials—could reshape second-line and beyond treatment algorithms, improving outcomes while potentially lowering hospitalizations from disease progression.

The phase 1 ARC-20 trial of casdatifan, an oral inhibitor of hypoxia-inducible factor-2 alpha (HIF-2α), has delivered early but compelling evidence of durable tumor responses in patients with heavily pretreated clear cell renal cell carcinoma (ccRCC). Published in Nature on July 28, 2026, the multi-center study enrolled 127 patients whose disease had progressed after multiple lines of therapy—a population with a dismal prognosis and few remaining options. The findings mark the first clinical validation of a next-generation HIF-2α antagonist specifically designed to overcome the limitations of earlier molecules in this class, offering a potential new niche in the increasingly crowded kidney cancer armamentarium.

“

Jamie Merchan, M.D., co-leader of the Translational and Clinical Oncology Research Program at Sylvester Comprehensive Cancer Center and a co-author of the study, underscored the translational angle.

Clear cell RCC is driven primarily by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene, which leads to constitutive stabilization of HIF-2α, a transcription factor that orchestrates tumor growth, angiogenesis, and metabolic reprogramming even in the oxygen-poor microenvironment characteristic of these tumors. While Merck’s belzutifan (Welireg) became the first HIF-2α inhibitor to secure FDA approval—initially for VHL disease-associated tumors and later for advanced ccRCC—its clinical activity in the refractory setting has been modest, with objective response rates hovering around 25% and a median progression-free survival of roughly 5-7 months. Researchers have long sought a more potent and selective inhibitor capable of achieving higher intratumoral drug levels without widening toxicity. Casdatifan, with optimized pharmacokinetic properties and enhanced binding affinity, was engineered to fill that gap.

The ARC-20 study was a dose-escalation and expansion trial that assessed casdatifan monotherapy in patients who had exhausted standard options, including VEGF-targeted agents and immune checkpoint inhibitors. The data released in Nature confirm that at the recommended phase 2 dose, casdatifan produced confirmed objective responses and durable disease control, accompanied by a manageable safety profile dominated by grade 1–2 anemia—an on-target effect of HIF-2α inhibition related to erythropoietin suppression—and fatigue, with no new or unanticipated toxicities. The specific response rate, duration of response, and progression-free survival metrics are detailed in the full publication, but the overarching message from investigators is that the agent can achieve clinically meaningful tumor shrinkage that lasts, even late in the disease course.

Jamie Merchan, M.D., co-leader of the Translational and Clinical Oncology Research Program at Sylvester Comprehensive Cancer Center and a co-author of the study, underscored the translational angle. “These findings are encouraging and suggest we may be able to better understand which patients benefit from targeting this pathway,” he said—a nod to the parallel biomarker analyses embedded in the trial. Indeed, one of the most exciting dimensions of ARC-20 is its effort to correlate pre-treatment tumor profiles with response, a step toward precision oncology that could help avoid futile therapy and focus resources on patients most likely to benefit.

From a competitive standpoint, casdatifan now enters a dynamic landscape. Belzutifan’s foothold is growing, and several other HIF-2α inhibitors, including those from Arcus Biosciences and NiKang Therapeutics, are in early development. However, casdatifan’s oral formulation and the quality of its phase 1 data—published in a top-tier journal—could accelerate its path into pivotal trials and potential partnership or acquisition interest. If subsequent randomized studies confirm superior efficacy or a more favorable tolerability window, the agent could reshape the treatment paradigm, perhaps in combination with checkpoint inhibitors or as maintenance therapy after first-line regimens.